Titlebook: Resistance to Ibritumomab in Lymphoma; Makoto Hosono,Jean-Fran?ois Chatal Book 2018 Springer International Publishing AG, part of Springer

indubitable

Features of Ibritumomab as Radionuclide Therapy,tes and other health authorities of nations. There are advantages of ibritumomab tiuxetan over other radioimmunotherapy drugs that have been studied so far. Theranostic aspects will provide interesting findings on the tumor characteristics and the dosimetry of tumor and normal tissues.

休戰(zhàn)

Radiation Dosimetry in Ibritumomab Therapy,apter the steps for dosimetry-based treatment planning are presented and discussed. These are a prerequisite for adequate determination of the dose-response relationship in clinical trials which in turn is required for optimal individual treatment planning.

Barter

Combining RAIT and Immune-Based Therapies to Overcome Resistance in Cancer?,unotherapy. In this chapter, we first review the immunogenic properties of irradiation before discussing available evidence of the benefits of radiation therapy and immunotherapy combinations in the context of lymphoma.

Insulin

Resistance and Heterogeneity of Intratumoral Antibody Distribution,ally relevant and rapidly evolving fields of cancer research. Despite this growing excitement in the fundamental research, tumor heterogeneity has little practical impact on today’s management of cancer patients..Therefore, understanding the mechanisms for resistance to ibritumomab tiuxetan and developing treatment strategies are important.

運(yùn)氣

Prospects for Enhancing Efficacy of Radioimmunotherapy,uding new antibody specificities, pretargeting methods, fractionated injections, and the use of alpha emitters. Immuno-PET is also likely to assist in selecting patients for radioimmunotherapy, optimizing injected activities, and noninvasively monitoring therapy efficacy.

減去

2196-5501 logical aspects, radiological and nuclear medicine aspects, and medical physics that deal with radiation dosimetry, and will outline future prospects for overcoming resistance and enhancing efficacy of ibritumomab..978-3-030-08652-7978-3-319-78238-6Series ISSN 2196-5501 Series E-ISSN 2196-551X

細(xì)菌等

ironic

Clinical Use and Efficacy of Ibritumomab in B Cell Lymphoma,(NHL) who have relapsed disease after first-line chemotherapy regimens and are reluctant to the precedent therapy. The overall response rate (ORR) of 80–90% and the complete response rate (CR) of 30–69% have been reported for patients with relapsed or refractory low-grade B cell NHL. It has also an

最有利

Biology and Pathology of B-Cell Lymphoma,second-line therapies. The target molecule of RIT is CD20, and the clinical outcomes have been demonstrated even in the lack of phase III studies to clearly define the efficacy of RIT. However, the best practice to employ RIT is still controversial. CD20 is an activated-glycosylated phosphoprotein e

Expostulate